MX2019014366A - Inhibidores de fgfr2 para el tratamiento del colangiocarcinoma. - Google Patents

Inhibidores de fgfr2 para el tratamiento del colangiocarcinoma.

Info

Publication number
MX2019014366A
MX2019014366A MX2019014366A MX2019014366A MX2019014366A MX 2019014366 A MX2019014366 A MX 2019014366A MX 2019014366 A MX2019014366 A MX 2019014366A MX 2019014366 A MX2019014366 A MX 2019014366A MX 2019014366 A MX2019014366 A MX 2019014366A
Authority
MX
Mexico
Prior art keywords
cholangiocarcinoma
treatment
patient
fgfr2
fgfr2 inhibitors
Prior art date
Application number
MX2019014366A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019014366A publication Critical patent/MX2019014366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En el presente documento se divulgan métodos para tratar el colangiocarcinoma en un paciente que comprenden: evaluar una muestra biológica del paciente para determinar la presencia de uno o más mutantes de FGFR que incluyen al menos el FGFR2 SNP C383R; y tratar al paciente con un inhibidor de FGFR si uno o más mutantes de FGFR que incluyen al menos el FGFR2 SNP C383R están presentes en la muestra.
MX2019014366A 2017-06-02 2018-06-01 Inhibidores de fgfr2 para el tratamiento del colangiocarcinoma. MX2019014366A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP18171315 2018-05-08
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Publications (1)

Publication Number Publication Date
MX2019014366A true MX2019014366A (es) 2020-07-27

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014366A MX2019014366A (es) 2017-06-02 2018-06-01 Inhibidores de fgfr2 para el tratamiento del colangiocarcinoma.

Country Status (15)

Country Link
US (2) US11707463B2 (es)
EP (1) EP3634414A1 (es)
JP (2) JP2020521794A (es)
KR (1) KR20200010505A (es)
CN (1) CN111050769A (es)
AU (1) AU2018278271A1 (es)
BR (1) BR112019025056A2 (es)
CA (1) CA3064317A1 (es)
IL (1) IL271058A (es)
JO (1) JOP20190280A1 (es)
MA (1) MA49248A (es)
MX (1) MX2019014366A (es)
PH (1) PH12019502710A1 (es)
UA (1) UA126478C2 (es)
WO (1) WO2018220206A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
KR20210126654A (ko) * 2019-02-12 2021-10-20 얀센 파마슈티카 엔.브이. 암 치료
KR20210145211A (ko) * 2019-03-29 2021-12-01 얀센 파마슈티카 엔.브이. 요로상피세포암종의 치료를 위한 fgfr 티로신 키나제 저해제
CN114144180A (zh) * 2019-05-28 2022-03-04 Qed医药股份有限公司 治疗胆管癌的方法
WO2021023178A1 (zh) * 2019-08-05 2021-02-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗fgfr2基因变异的肿瘤的药物中的用途
CN114945367A (zh) * 2020-01-17 2022-08-26 贝达医药公司 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
KR20100015883A (ko) * 2007-03-23 2010-02-12 더 트랜스내셔날 게노믹스 리서치 인스티튜트 자궁내막암 및 전암을 진단，분류 및 치료하는 방법
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor

Also Published As

Publication number Publication date
AU2018278271A1 (en) 2019-12-05
WO2018220206A1 (en) 2018-12-06
US11707463B2 (en) 2023-07-25
PH12019502710A1 (en) 2020-06-08
MA49248A (fr) 2020-04-15
US20240016801A1 (en) 2024-01-18
IL271058A (en) 2020-01-30
CA3064317A1 (en) 2018-12-06
JP2020521794A (ja) 2020-07-27
US20200138809A1 (en) 2020-05-07
CN111050769A (zh) 2020-04-21
KR20200010505A (ko) 2020-01-30
JOP20190280A1 (ar) 2019-12-02
BR112019025056A2 (pt) 2020-06-16
JP2023113650A (ja) 2023-08-16
UA126478C2 (uk) 2022-10-12
EP3634414A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
PH12017500556A1 (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12017501064A1 (en) Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина
MX2018008166A (es) Sistemas y metodos para confirmar la activacion de indicadores biologicos.
WO2015120094A3 (en) Method of identifying tyrosine kinase receptor rearrangements in patients
ATE555212T1 (de) Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
MX2017003832A (es) Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr.
MX2017011512A (es) Metodos de visualizacion de la sensibilidad antimicrobiana de cepas aisladas biologicas.
WO2015187953A3 (en) Method for direct microbial identification
IL290202A (en) Methods and kits to identify the source of a blood clot and to optimize treatment in a post-ischemic event
EA201992849A1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
PH12021550628A1 (en) Treatment of cholangiocarcinoma
WO2016071770A3 (en) Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
WO2017011559A8 (en) Compositions and methods for treating cancer
UA95590U (uk) Спосіб прогнозування зрощення перелому
UA104426U (uk) Спосіб прогнозування зрощення перелому
UA96076U (uk) Спосіб прогнозування зрощення перелому
UA102757U (uk) Спосіб оцінки ризику повторного або рецидивуючого тромботичного ускладнення у пацієнтів з гострим коронарним синдромом без елевації сегмента st
UA96017U (uk) Спосіб прогнозування зрощення перелому